Q2 EPS Estimate for MAIA Biotechnology Lifted by Analyst

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Investment analysts at Diamond Equity upped their Q2 2026 earnings per share (EPS) estimates for MAIA Biotechnology in a report issued on Monday, May 18th. Diamond Equity analyst H. Diamond now anticipates that the company will earn ($0.11) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($0.69) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q3 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.52) EPS.

MAIA Biotechnology Stock Down 2.4%

Shares of NYSEAMERICAN MAIA opened at $1.23 on Wednesday. The business’s 50 day moving average price is $1.36 and its 200 day moving average price is $1.51. The firm has a market cap of $74.78 million, a P/E ratio of -1.84 and a beta of 0.21. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently bought and sold shares of MAIA. Corsair Capital Management L.P. purchased a new stake in MAIA Biotechnology in the 1st quarter worth approximately $140,000. Jane Street Group LLC purchased a new stake in MAIA Biotechnology in the 4th quarter worth approximately $120,000. Geode Capital Management LLC boosted its position in MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after purchasing an additional 25,684 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in MAIA Biotechnology in the 4th quarter worth approximately $35,000. Finally, Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.